Top View
- Targeted Therapy for Lung Cancer (Faculty Presentations)
- Central Nervous System Relapse of Systemic ALK-Rearranged Anaplastic Large Cell Lymphoma Treated T with Alectinib
- Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL
- In Vitro and in Vivo Anti-Tumor Activity of Alectinib in Tumor Cells with NCOA4-RET
- Update on Molecular Pathology and Role of Liquid Biopsy in Nonsmall Cell Lung Cancer
- New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer
- Bladder Cancer
- Lorlatinib) Tablets, for Oral Use Interstitial Lung Disease/Pneumonitis: Immediately Withhold Initial U.S
- Resistance to ALK Targeting Therapies As a Gradual Darwinian Adaptation to Inhibitor Specific Selective Pressures
- Strategic Collaboration in Oncology Trastuzumab Deruxtecan (DS-8201)
- Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer
- Alectinib: Drug Information
- Brentuximab Vedotin - Drugbank
- Targeting the Microenvironment of Brain Metastases
- Phase II Trial of CH5424802 (Alectinib Hydrochloride
- Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use Between 2013 and 2017
- Anaplastic Large Cell Lymphoma: Pathology, Genetics, and Clinical Aspects
- Oncology Agents Policy #: Rx.01.67
- ALECENSA (Alectinib) Is a Kinase Inhibitor for Oral Administration
- Proton Pump Inhibitors and Oncologic Treatment Efficacy
- Research at Scale—Exploring What Is Possible with High-Quality Real-World Data
- List of Cleared Or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools)
- Alectinib Shows Potent Antitumor Activity Against RET-Rearranged Non–Small Cell Lung Cancer
- Focus on ALK-Rearranged Non-Small Cell Lung Cancer (NSCLC)
- Management of Acquired Resistance to ALK Inhibitors: Repeat Biopsy to Characterize Mechanisms of Resistance Does Not Significantly Impact Clinical Outcomes
- Pharmacology Review(S) Memorandum
- Randomized, Multicenter, Phase Iii, Open
- Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and Beyond
- YAP1 Mediates Survival of ALK-Rearranged Lung Cancer Cells Treated with Alectinib Via Pro-Apoptotic Protein Regulation
- Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer with High Tumor
- Eunethta Joint Action 3 WP4 ALECTINIB AS MONOTHERAPY
- Alectinib (CH5424802) Antagonizes ABCB1- and ABCG2-Mediated Multidrug Resistance in Vitro, in Vivo and Ex Vivo
- Alecensa: Assessment Report
- Brain Metastases in NSCLC – Are Tkis Changing the Treatment Strategy?
- An Open‐Label Phase
- ALECENSA® (Alectinib) Fact Sheet
- Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer
- Alecensa 150 Mg Hard Capsules
- Efficacy of Combination Treatment Using YHO-1701, an Orally Active
- Alectinib in RET-Rearranged Non-Small Cell Lung Cancer—Another Progress in Precision Medicine?
- Overcoming EGFR Bypass Signal-Induced Acquired
- Drug-Related Pneumonitis in Cancer Treatment During the COVID-19 Era
- Lorbrena® (Lorlatinib) P&T Approval Date 12/2018, 12/2019, 12/2020 Effective Date 3/1/2021; Oxford Only: 3/1/2021
- Roche to Present New Data from Its Broad Oncology Portfolio at The
- LORBRENA (Lorlatinib) Is a Kinase Inhibitor for Oral Administration
- Chemotherapeutic and Biologic Drugs
- Combining Radiation Therapy with ALK Inhibitors in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer (NSCLC): a Clinical and Preclinical Overview
- Alectinib for the Treatment of Metastatic ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib
- Tyrosine Kinase Receptors in Oncology